Skip to main content
Premium Trial:

Request an Annual Quote

University of Chicago Licenses PGx Test to Mayo

NEW YORK, Dec. 29 (GenomeWeb News) - University of Chicago researchers licensed a pharmacogenomics test for colorectal cancer patients to teh Mayo Clinic, the university said last week.


The UGT1A1 test determines which patients are likely to have an adverse reaction to irinotecan hydrochloride (Camptosar), a key component of the standard first-line treatment for advanced cancers of the colon and rectum.


Through this licensing agreement, the clinic's reference laboratory, Mayo Medical Laboratories, will provide the test to patients nationwide.


Mayo acquired an exclusive license from the university, as well as the right to sub-license the test.


Mayo recently sub-licensed the rights under the University of Chicago patent to Third Wave Technologies. While Third Wave received FDA approval for the genetic test in August, only patients enrolled in studies at the University of Chicago previously had access to it.


In June, the FDA relabeled Camptosar to include a warning that patients with a particular UGT1A1 genotype should receive a lower starting dose.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.